# A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema

> **NCT04527107** · PHASE2 · COMPLETED · sponsor: **Oxurion** · enrollment: 135 (actual)

## Conditions studied

- Diabetes Mellitus
- Diabetic Retinopathy
- Diabetic Macular Edema

## Interventions

- **DRUG:** THR-149 dose level 1
- **DRUG:** THR-149 dose level 2
- **DRUG:** THR-149 dose level 3
- **DRUG:** THR-149 0.13mg
- **DRUG:** THR-149 0.13mg + aflibercept 2mg
- **DRUG:** aflibercept 2mg + THR-149 0.13mg
- **DRUG:** Aflibercept 2mg

## Key facts

- **NCT ID:** NCT04527107
- **Lead sponsor:** Oxurion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-31
- **Primary completion:** 2023-09-28
- **Final completion:** 2023-11-22
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2023-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04527107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04527107, "A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04527107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*